Tulane Ventures, an early-stage investment fund launched by the Tulane University Innovation Institute, has invested $250,000 in Exactics, a biotech startup co-founded by Tulane senior Dylan Murray. The company is developing multiple at-home tests for infectious diseases, starting with a rapid test that will allow users to determine if a tick carries the pathogen that causes Lyme disease.
In a biotech field dominated by seasoned researchers, Exactics is showing that undergraduates can also develop fast, practical solutions to urgent health challenges. The startup was founded by students from the University of Chicago and Tulane. Its flagship product, the TiCK Test, works like an at-home COVID-19 test.
“You take a tick off yourself, your dog or your horse, and put it in our test,” said Murray, Exactics chief operating officer. “In 15 minutes, it tells you whether that tick has transmitted Lyme disease in the last 24 hours — so you know to get treated right away.”
Full story: Tulane Ventures invests in student-led startup to develop rapid Lyme test | Tulane University News
